BCG vaccine - Vakzine Project Management/Serum Institute of India

Drug Profile

BCG vaccine - Vakzine Project Management/Serum Institute of India

Alternative Names: BCG-vaccine-Vakzine-Projekt-Management; rBCG-delta-ureC-Hly; rBCGdeltaUreCHly; VPM-1002; VPM-1002BC

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Max Planck Institute for Infection Biology
  • Developer Serum Institute of India; Swiss Group for Clinical Cancer Research; Vakzine Projekt Management
  • Class Antituberculars; Tuberculosis vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis
  • Phase I/II Bladder cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Tuberculosis(Prevention) in Germany (IM, Injection)
  • 04 May 2017 Serum Institute of India plans a phase II/III trial for Tuberculosis(Prevention) in India (CTRI2017-03-008266)
  • 18 Aug 2015 Phase-II development is ongoing for Tuberculosis (In neonates, Prevention) in South Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top